Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure
- JACC Basic Transl Sci. 2018 Nov 12;3(5):625-638. doi: 10.1016/j.jacbts.2018.07.003.
- 1. Pharmaceutical R&D Consulting, LLC, Loveland, Colorado.
- 2. QTest Labs, LLC, Columbus, Ohio.
- 3. Revivo Therapeutics, Inc., Durham, North Carolina.
- 4. Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan.
The effects of the nitroxyl donor BMS-986231 on hemodynamics, left ventricular (LV) function, and pro-arrhythmic potential were assessed using canine heart failure models. BMS-986231 significantly (p < 0.05) increased LV end-systolic elastance, pre-load-recruitable stroke work, ejection fraction, stroke volume, cardiac output, ratio of early-to-late filling time integrals, and early mitral valve inflow velocity deceleration time. BMS-986231 significantly decreased LV filling pressures, end-diastolic stiffness, the time-constant of relaxation, end-diastolic wall stress, systemic vascular resistance, and myocardial oxygen consumption. BMS-986231 had little effect on heart rate and did not induce de novo arrhythmias. Thus, BMS-986231 has beneficial inotropic, lusitropic, and vasodilatory effects.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Drug IntermediateResearch Areas: Cardiovascular Disease